Journal: Frontiers in Neurology

Article Title: Correlation between electrode location and clinical efficacy of deep brain stimulation of the globus pallidus internus in isolated generalized dystonia

doi: 10.3389/fneur.2026.1779301

Figure Lengend Snippet: Predictors of motor outcomes after GPi-DBS. A simple linear regression model was constructed to assess candidate predictive factors for movement outcomes, including baseline variables (demographic and clinical). Significant negative correlations were observed between motor outcome and preoperative HAMA (E) , preoperative HAMD (F) , while Disease duration (A) , Age at surgery (B) , Age of onset (C) , Preoperative BFMDRS-M total score (D) , MMSE score ( G) and MOCAscore (H) showed no significant correlations.

Article Snippet: This study included patients with IGD who underwent bilateral GPi-DBS treatment in the Department of Functional Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, from January 2016 to December 2021, and had complete follow-up data.

Techniques: Construct

Journal: Frontiers in Neurology

Article Title: Correlation between electrode location and clinical efficacy of deep brain stimulation of the globus pallidus internus in isolated generalized dystonia

doi: 10.3389/fneur.2026.1779301

Figure Lengend Snippet: Predictors of motor outcomes after GPi-DBS. A simple linear regression model was constructed to assess candidate predictive factors for movement outcomes, including baseline variables (demographic and clinical). Significant negative correlations were observed between motor outcome and preoperative HAMA (E) , preoperative HAMD (F) , while Disease duration (A) , Age at surgery (B) , Age of onset (C) , Preoperative BFMDRS-M total score (D) , MMSE score ( G) and MOCAscore (H) showed no significant correlations.

Article Snippet: A total of 17 IGD patients who received bilateral GPi-DBS at Beijing Tiantan Hospital from January 2016 to December 2021 and had complete follow-up data were enrolled.

Techniques: Construct

Journal: Clinical Interventions in Aging

Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

doi: 10.2147/CIA.S600031

Figure Lengend Snippet: Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

Article Snippet: Patients were included in this study if they met the following conditions: (1) diagnosed with idiopathic PD according to the Movement Disorders Society (MDS) Clinical Diagnostic Criteria and the UK Brain criteria with the presence of disabling LID symptoms (with typical clinical symptoms such as levodopa-induced involuntary chorea/choreoathetoid movements and a total score greater than 0 on the UDysRS ) not optimized with anti-PD medications, confirmed by at least two qualified senior movement disorder specialists; (2) received bilateral STN-DBS between January 2019 and December 2021 at Beijing Tiantan Hospital, Capital Medical University; and (3) without dementia, severe psychiatric disorders, severe brain atrophy or cerebral ischemic lesions, or systemic diseases that interfered with the surgery.

Techniques: Functional Assay

Journal: Clinical Interventions in Aging

Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

doi: 10.2147/CIA.S600031

Figure Lengend Snippet: Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

Article Snippet: Patients were included in this study if they met the following conditions: (1) diagnosed with idiopathic PD according to the Movement Disorders Society (MDS) Clinical Diagnostic Criteria and the UK Brain criteria with the presence of disabling LID symptoms (with typical clinical symptoms such as levodopa-induced involuntary chorea/choreoathetoid movements and a total score greater than 0 on the UDysRS ) not optimized with anti-PD medications, confirmed by at least two qualified senior movement disorder specialists; (2) received bilateral STN-DBS between January 2019 and December 2021 at Beijing Tiantan Hospital, Capital Medical University; and (3) without dementia, severe psychiatric disorders, severe brain atrophy or cerebral ischemic lesions, or systemic diseases that interfered with the surgery.

Techniques: Functional Assay